Conclusions
Low dose (500mg) intravenous FCM treatment was not equivalent to 1000mg
within a 5% margin for successful correction of ID in pregnancy. A
single 1000mg does represents an efficient and effective method to
clinically manage ID and IDA in pregnancy. A lower dose approach
requires ongoing monitoring to ensure adequate iron stores are reached
and sustained. Both doses had no adverse impact on neonatal or child
outcomes.